Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
120 hedge funds and large institutions have $230M invested in Mersana Therapeutics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 36 reducing their positions, and 22 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 36
19% more call options, than puts
Call options by funds: $1.5M | Put options by funds: $1.26M
0.14% less ownership
Funds ownership: 3.87% → 3.73% (-0.14%)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
2% less funds holding
Funds holding: 122 → 120 (-2)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
56% less capital invested
Capital invested by funds: $526M → $230M (-$297M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$16.4M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$5.69M |
| 3 |
Goldman Sachs
New York
|
+$1.66M |
| 4 |
Two Sigma Advisers
New York
|
+$1.63M |
| 5 |
JP Morgan Chase
New York
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$16.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.14M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.24M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$3.59M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.6M |
MRSN Hedge Fund Activity: Q2 2024 in Review
120 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q2 2024, worth a combined $230M — down 56% from $526M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of MRSN and 20 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 44 added.
The largest buyer was Nextech Invest, adding an estimated $16.4M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $16.4M sold.
- 120 institutional investors held Mersana Therapeutics (MRSN) as of Q2 2024, down from 122 in Q1 2024.
- Funds reported $230M of Mersana Therapeutics stock for Q2 2024, down 56% quarter-over-quarter.
- 20 funds opened new Mersana Therapeutics positions in Q2 2024 and 22 closed out, a net change of -2 holders.
- The largest Mersana Therapeutics buyer in Q2 2024 was Nextech Invest, an estimated $16.4M added.
- The largest Mersana Therapeutics seller in Q2 2024 was Balyasny Asset Management, an estimated $16.4M sold.
Based on aggregated 13F filings for Q2 2024.